Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.74 |
| ▸ | NQO1 | P15559 | 7/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.68 |
| ▸ | CRHBP | P24387 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | CASP6 | P55212 | 1/20 | 0.67 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TOP1 | P11387 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7362123 | 0.89 | NQO1 (0.64) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL8336015 | 0.86 | THRB (0.64) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL7349603 | 0.85 | VKORC1 (1.00) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL7896856 | 0.85 | NQO1 (1.00) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL7355113 | 0.85 | NQO1 (0.94) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL18126686 | 0.85 | NQO1 (0.78) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL30854907 | 0.84 | NQO1 (0.67) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL14172134 | 0.84 | NQO1 (0.68) | VKORC1NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL7352926 | 0.82 | NQO1 (0.69) | VKORC1NQO1CYP2C9TOP1KDM4E | |
| SCHEMBL7351597 | 0.82 | CYP2C9 (0.82) | VKORC1NQO1CYP2C9CRHBPCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | claimed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | claimed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | claimed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | claimed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. | 2007-06-07 | — | — | US | disclosed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | CES1, F2, CYP3A5 | VKORC1 6/4885NQO1 249/4885CYP2C9 24/4885 |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | CES1, F2, CYP3A5 | VKORC1 6/4885NQO1 249/4885CYP2C9 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.